We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results...
Read ArticleHealthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as...
Read ArticleCynata Therapeutics flags three trial results in the short term for three different conditions, inc...
Read ArticleASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing;...
Read ArticleVolatility remained the status quo as the ASX200 ended down 0.23%. The local bourse briefly touch...
Read ArticleThe ASX dropped, dragged down by Real Estate and Mining stocks Qantas cuts former CEO’s compensatio...
Read ArticleCynata Therapeutics Ltd (ASX:CYP) has seen its share price rise more than 10% on the release of a st...
Read ArticleTo register for Friday's webinar click here. NOVONIX (ASX:NVX) and CBMM has joined forces to devel...
Read ArticleS&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expec...
Read ArticleThe EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-l...
Read ArticleThe ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biot...
Read ArticleImricor completes installation of iCMR capital equipment at Lausanne University Hospital in Switzer...
Read ArticleASX rose as the RBA held interest rates at 12-year high 4.35pc All 11 sectors on the ASX gained, w...
Read ArticleS&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biot...
Read ArticleResearch shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase th...
Read ArticleSpecial Report: A recent lunch put together in Sydney by Jane Morgan Management and Éthica Capital s...
Read ArticleMomentum trading involves taking advantage of, and making profits from, upward trends in a stock. Th...
Read ArticleInvestors got the chance to get up close and personal with ASX technology and biotech companies in S...
Read ArticleASX Health sector was in correction territory in April Why is the health sector different from othe...
Read ArticleThere’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to c...
Read ArticleMELBOURNE, Australia, April 8, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX: "CYP", "Cynata"...
Read ArticleBiotech company Cynata Therapeutics (ASX:CYP) received regulatory and ethics approval in the Europea...
Read ArticleLocal markets end lower on big bank sell-off Material gains offset by Telco’s and Financials Small...
Read ArticlePeter Milios: I am Peter Milios from the Finance News Network, and today I am talking with Cynata...
Read ArticleASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essenti...
Read ArticleCynata Therapeutics’ (ASX:CYP) announces the enrolment and treatment of the first participant (CYP-0...
Read ArticleMELBOURNE, Australia, March 5, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX: "CYP", "Cynata"...
Read ArticleHealius has new CEO Nove Eye reports record US sales in February Cynata says first patient has been...
Read ArticleViking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
Read ArticleMELBOURNE, Australia, Feb. 26, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX: "CYP", "Cynata"...
Read ArticleRecce Pharma says Phase 1/2 study is achieving primary endpoints Cynata also reports also reports g...
Read ArticleASX200 trims gains to end circa 0.3pc higher Sectors in the money include Utilities and IT Small...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleAlthea extends contract in Canada Clarity moves forward to cohort 3 Cynata opens Phase 2 recruitmen...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleMedibio jumps after completing Phase 1 clinical trial Cann Group’s latest crop harvest is at a scal...
Read ArticleThe changing of the guard is not just evident at Buckingham Palace: barely a week goes by without an...
Read ArticleS&P/ASX 200 closes well in the red today: -1.24% after US stocks dipped on the back of Fed hawk...
Read ArticleAustralian clinical-stage cell therapy company Cynata Therapeutics (ASX:CYP) has announced t...
Read ArticleThe ASX200 closed the 2023 financial year marginally higher, ahead of significant Labor Government c...
Read ArticleCynata Therapeutics (CYP) appoints Dr Kilian Kelly as its CEO and Managing Director, effective July...
Read ArticleHighlights Dr Kilian Kelly has been appointed to the position of Cynata’s Chief Executive Office...
Read ArticleBiotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We...
Read ArticleThe ASX closed out the day flat, thanks to a last-minute selling spree Qantas announces record prof...
Read ArticleHighlights Cynata will present two-year patient follow-up data from its Phase 1 clinical trial...
Read Article‘More of the same’ since lunchtime saw the benchmark land at -0.25% for the day Health Care coughed...
Read ArticleHighlights Together with the placement of AU$5 million, Cynata has been able to raise total proc...
Read ArticleHighlights Cynata is testing the safety and efficacy of CYP-006TK in diabetic foot ulcers (DFUs)...
Read ArticleThe S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chi...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleClinical-stage cell therapy company Cynata Therapeutics (ASX:CYP) has received approval from...
Read ArticlePharmaxis widens clinical trial following FDA guidance Aroa receives US FDA 510K clearance Cynata g...
Read ArticleHighlights Cynata previously received green light from the US FDA (Investigational New Drug appl...
Read ArticleHighlights The placement of New Shares of Cynata Therapeutics is at the Offer Price of AU$0.215...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleThe ASX jumped 0.3% after lunch as the RBA finally kept rates on hold. XGD All Ordinaries Gold soar...
Read ArticleHighlights Cynata Therapeutics has added three new sites to the ongoing clinical trial of its co...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticleCell therapy company Cynata Therapeutics (ASX:CYP) has received approval to commence the pro...
Read ArticleCynata Therapeutics (CYP) receives approval to launch a phase two clinical trial in acute graft-vers...
Read ArticleHighlights Cynata has secured approval to start the proposed aGvHD phase 2 clinical trial in the...
Read ArticleCynata Therapeutics’ chief medical officer, Jolanta Airey, gives a step-by-step guide on what biote...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticleHighlights Cynata has received a Notice of Acceptance from IP Australia for a patent describing...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleHighlights The ASX 200 benchmark index closed in green today (November 11), gaining 194.00 point...
Read ArticleCynata Therapeutics (CYP) receives notice of allowance for a patent application covering its Cymerus...
Read ArticleCynata gets Notice of Allowance from US Patent Office Proteomics secures patent in Hong Kong Ramsay...
Read ArticleKey Highlights: Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlan...
Read ArticleCynata Therapeutics (CYP) receives funding for its new clinical trial of Cymerus MSCs for kidney tra...
Read ArticleHitIQ has entered into a two-year deal with the Premier League for its concussion management tech H...
Read ArticleWe take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks fr...
Read ArticlePatrys crosses blood brain barrier in health animals Cynata receives Notice of Acceptance from IP A...
Read ArticleCynata Therapeutics (CYP) reveals an independent data safety monitoring board (DSMB) completes its r...
Read ArticleCynata gets green light for clinical trial from an independent review Apiam acquires large vet busi...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleSt Vincent’s Institute of Medical Research has been awarded about $1m to investigate mesenchymal ste...
Read ArticleCynata Therapeutics (CYP) is set to investigate its Cymerus mesenchymal stem cells (MSCs) as a treat...
Read ArticleBotanix submits NDA to the US FDA Pharmaxis reports on latest clinical trials PainChek to expand to...
Read ArticleThe federal government's National Health and Medical Research Council will provide a $1 mill...
Read ArticleCell therapy company Cynata Therapeutics (ASX:CYP) has announced the appointment of Janine R...
Read ArticleAvita Medical’s top line results on RECELL disappoint investors Cynata has completed a strategic re...
Read ArticleCynata Therapeutics (CYP) completes a strategic review of its clinical development pipeline to maxi...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticleCynata Therapeutics (CYP) receives a notice of allowance for its Cymerus mesenchymal stem from the...
Read ArticleCynata receives notice from the US Patent Office GTG completes acquisition of AffinityDNA Dental cl...
Read ArticleCell therapy company Cynata Therapeutics (ASX:CYP) has secured a US patent covering the use...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticleHighlights Gold prices fell sharply as the strong US dollar and rise in Treasury yields put pres...
Read ArticleCynata Therapeutics, a Melbourne biotechnology company specialising in stemcell therapeutics, has li...
Read ArticleAustralian cell therapy company Cynata Therapeutics (ASX:CYP) has announced that St George H...
Read ArticleKey Highlights: US FDA has cleared Cynata’s IND application for a Phase 2 clinical trial of CYP-001...
Read ArticleMelbourne-based stemcell biotechnology company Cynata Therapeutics has got the green light from the...
Read ArticleCynata Therapeutics (CYP) receives approval from the US Food and Drug Administration (FDA) to comme...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleCynata Therapeutics has started clinical trials of its patented polymer-coated silicon wound dressin...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleChina’s patent office has advised cell therapeutics biotech Cynata Therapeutics that it will be give...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read ArticleAustralian medical device company and global supplier of rapid diagnostic testing devices (RDT), Ato...
Read ArticleStem cell biotech business Cynata Therapeutics is boosting its IP protection after being advised it...
Read ArticleCynata Therapeutics has lopped over $800,000 off its tax bill after the company’s cutting-edge cell...
Read ArticleStem cell therapy, sometimes called regenerative medicine, is one of the most exciting areas of the...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleCynata Therapeutics has secured a manufacturing services agreement with specialised human cell manuf...
Read ArticleThe Cynata Therapeutics Limited (ASX: CYP) share price is in the green today following news of a co...
Read ArticleCynata Therapeutics (CYP) executes a manufacturing services agreement with FUJIFILM Cellular Dynami...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleCynata Therapeutics has launched a clinical trial on its Cymerus mesenchymal stem cell product used...
Read ArticleCynata Therapeutics (CYP) has commenced a clinical trial of its dressing technology (CYP-006TK) in...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticleCynata Therapeutics has taken a vital step to conducting a clinical trial on its Cymerus product use...
Read ArticleSYDNEY, Oct. 16, 2021 /PRNewswire/ — Ensuring healthy lives and promoting physical and mental wel...
Read ArticleClinical-stage biotechnology company, Cynata Therapeutics has received a regulatory tick of approval...
Read ArticleThe ASX had a positive end to the week with the ASX 200 gaining 0.87% today taking its weekly gain t...
Read ArticleThe ASX 200 health stocks index (XHJ) had risen by 0.30% at the time of writing, compared to the bro...
Read ArticleKey highlights Cynata and Fujifilm have entered into a new strategic partnership which includes de...
Read ArticleBiotechnology company Cynata Therapeutics has sealed a partnership agreement with Fujifilm as it mov...
Read ArticleBiotechnology company Cynata Therapeutics has received high-level coverage of its work on stem cell...
Read ArticleCell therapy company Cynata Therapeutics (ASX:CYP) has announced that a scientific paper des...
Read ArticleASX-listed clinical-stage biotechnology group Cynata Therapeutics is set to notch up yet another pat...
Read ArticleShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with pre...
Read ArticleShareCafeCell based therapeutic product platform Dr Ross Macdonald – Managing Director and Chief...
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read ArticleASX-listed clinical-stage stem cell and regenerative medicine group Cynata Therapeutics’ proprietary...
Read ArticleClinical-stage stem cell and regenerative medicine group Cynata Therapeutics looks to be on the verg...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleCynata Therapeutics has secured relevant ethics approval for a clinical trial on its Cymerus product...
Read ArticleCynata Therapeutics has appointed leading clinical research organisation Dataphram Australia to mana...
Read ArticleSummary The S&P/ASX 200 dropped 7.70 points or 0.11% to 7,300 by afternoon. The market sent...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleA recent article published in the Advance Science magazine discussed research by Monash University t...
Read ArticleEscrow Watch is Stockhead’s monthly recap of the ASX companies that are releasing shares currently i...
Read ArticleCynata Therapeutics has nailed an exclusive global licence agreement with TekCyte, a leading develop...
Read ArticleSummary The ASX 200 continued gaining momentum on Thursday, hitting a fresh record high. The ma...
Read ArticleIt was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies relea...
Read ArticleASX-listed clinical-stage stem cell and regenerative medicine group, Cynata Therapeutics has enrolle...
Read ArticleSummary Frontier Resources has successfully completed its landowner MRA Warden’s hearing as part...
Read ArticleSummary The ASX 200 trades higher by 15.20 points or 0.22% to 7045.50 at the close, led by gains...
Read ArticleThe capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the fir...
Read ArticleASX-listed clinical-stage stem cell and regenerative medicine group, Cynata Therapeutics is looking...
Read ArticleSummary Drug discovery company developing new therapies, Dimerix, has enrolled multiple patients...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleCynata Therapeutics has received ethics committee approval to expand the recruitment criteria of its...
Read ArticleSource:Cryptographer, Shutterstock Summary Stem cell and regenerative medicine player Cynata Th...
Read ArticleStem cell therapeutics company Cynata's (ASX: CYP) pool of eligible patients in a COVID-19 treatment...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read Article2021 is set to be another big year for ASX capital raisings with solid volumes so far in 2021. In th...
Read ArticleSource: Guschenkova, Shutterstock Summary Medical technology player Nova Eye Medical announced...
Read ArticleHaving already successfully demonstrated the efficacy and safety of its proprietary stem cells on ro...
Read ArticleCynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell t...
Read ArticleCynata Therapeutics has signed an MoU with TekCyte Pty Ltd to access its wound dressing technology i...
Read ArticleCOVID-19 vaccines have reached Australia but ASX stocks that were making anti-COVID 19 drugs or test...
Read ArticleCynata Therapeutics’ recent run of successful capital raisings has been bolstered by a lazy $1.39m t...
Read ArticleCynata Therapeutics (ASX: CYP), founded by two clever stem cell researchers and one wise Australian...
Read ArticleCynata Therapeutics (ASX: CYP), founded by two clever stem cell researchers and one wise Australian...
Read ArticleIf 2020 taught us anything, it was the importance of quality healthcare. The COVID-19 pandemic put...
Read ArticleSummary Healthcare firms across the world are working like a Trojan to seek an effective treatme...
Read ArticleASX large cap biotech Mesoblast (ASX:MSB) is not alone in fighting Acute Respiratory Distress Syndro...
Read ArticleMelbourne-based biotechnology company, Cynata Therapeutics, has commenced a Phase 3 clinical trial u...
Read ArticleMelbourne-based biotechnology company, Cynata Therapeutics, has commenced a Phase 3 clinical trial u...
Read ArticlePresenting companies were Cynata Therapeutics Ltd, Recce Pharmaceuticals Ltd and Pharmaxis Ltd (ASX:...
Read ArticleOngoing studies of Cynata Therapeutics’ Cymerus stem cell products are beginning to reveal a wide ra...
Read ArticleASX-listed Cynata Therapeutics, a Melbourne-based, clinical-stage biotech company specialising in ce...
Read ArticleShareCafeCynata Therapeutics – ShareCafe Hidden Gems Webinar Presentation Presenter – Dr. Ross Ma...
Read ArticleShareCafeHidden Gems Webinar Recap – OSL, MDC, CYP, GSS We continue to unearth small-cap companie...
Read ArticleCanary Capital is making a huge bet on a company that thinks stem cells aren’t the future of medicin...
Read ArticleAustralian company Cynata Therapeutics (ASX:CYP) says it has begun patient enrolment in its ...
Read ArticleThe Cynata Therapeutics Ltd (ASX: CYP) share price leapt by as much as 14% this morning as patient...
Read ArticleWhile treatments for pain management per se may not receive as much attention as those related to cu...
Read ArticleBy Tim Boreham, Editor, The New Criterion The ASX biotechs surfing the COVID-19 story Normally inves...
Read ArticleNormally investors shun speculative plays in times of market uncertainties, but that’s not been the...
Read ArticleStockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and pickin...
Read ArticleFortunes were to be made in ASX health stocks during March and April as investors looked for salvati...
Read ArticleIn the last fortnight another two dozen directors of ASX small caps made trades above $100,000 and a...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleCOVID-19 vaccines are driving markets but treatments are where most people believe a solution to the...
Read ArticleBiotechnology company Cynata Therapeutics (ASX: CYP) intends to develop a treatment for COVID-19 by...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticlePre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy acco...
Read ArticleOur summary of Cynata Therapeutics Ltd's recent announcement What's happened? Cynata Therapeutics Lt...
Read ArticleThe COVID-19 pandemic has led to 527 clinical trials being shut down in Australia and New Zealand th...
Read ArticleClinical-stage biotechnology company specialising in cell therapeutics Cynata Therapeutics (...
Read ArticleThe S&P/ASX 200 index (ASX: XJO) has followed the lead of U.S. markets and is trading notably l...
Read ArticleCynata Therapeutics (ASX: CYP) revealed it is in “active discussions” with international pharmaceuti...
Read ArticleAs with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time atta...
Read ArticleShareCafeAll The Dope On Emerald Clinics’ Limp Debut Having been long on promises but short on deliv...
Read ArticleThe Australian clinical-stage stem cell and regenerative medicine company is focused on the developm...
Read ArticleCynata Therapeutics (CYP) has received a notice of allowance from the Israel Patent Office for a pa...
Read ArticleCynata Therapeutics (CYP) has released its December 2019 quarterly report, primarily outlining posi...
Read ArticleCynata’s managing director Dr Ross Macdonald will present at Proactive’s CEO Sessions in Sydney on F...
Read ArticleWith triple the number of sepsis cases in Australia, small cap biotech company Cynata Therapeutics (...
Read ArticleIn a preclinical study in a mouse model of CLI, treatment with Cymerus MSCs led to significantly hig...
Read ArticleThe health sector was the most successful sector on the ASX in 2019. Various small caps made several...
Read ArticleCynata Therapeutics (CYP) has received approval from the U.K. Medicines and Healthcare products Reg...
Read Article14 Jan 2020 - Cell therapeutics company Cyanata (ASX:CYP) has received the greenlight from British m...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 136-odd small ca...
Read ArticleThe Cynata Therapeutics Ltd (ASX: CYP) share price was on form on Tuesday. The clinical-stage biote...
Read ArticleCynata Therapeutics (CYP) has received a research and development tax incentive of nearly $2 millio...
Read Article07 Jan 2020 - Biotechnology company Cynata Therapeutics (ASX:CYP) has received an almost $2 million...
Read ArticleThe Cynata Therapeutics Ltd (ASX: CYP) share price has jumped 9.8% after opening today, with CYP sh...
Read ArticlePre-clinical studies using Cynata Therapeutics’ (ASX: CYP) Cymerus mesenchymal stem cells in a sepsi...
Read ArticleThere are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so...
Read ArticleThe company is an Australian clinical-stage stem cell and regenerative medicine corporation focused...
Read ArticleHealth care system of Australia is considered as one of the best, globally, as it delivers safe and...
Read ArticleThe Cynata Therapeutics Ltd (ASX: CYP) share price has come under pressure on Thursday. Its shares...
Read ArticleAvecho Biotechnology (ASX:AVE), the company formerly known as Phosphagenics, announced that its Japa...
Read Article17 Oct 2019 - Biotech company Cynata Therapeutics (ASX:CYP) has decided to withdraw from acquisition...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleStrong gains among selected life science shares is fuelling optimism the sector may have further to...
Read ArticleAustralian regenerative medicine company Cynata Therapeutics (ASX:CYP) has announced it has...
Read ArticleDo you know that on this day in 1970 the great American rock guitarist, singer, and songwriter Jimi...
Read ArticleAustralian regenerative medicine company Cynata Therapeutics (ASX:CYP) has announced Fujifil...
Read ArticleOn Stockhead today, the gold M&A just keeps rolling with Azumah the latest takeover target, SRJ...
Read ArticleCynata Therapeutics Ltd [ASX:CYP] reported a massive win late last night. Their Japanese benefactor,...
Read ArticleFollowing a successful phase one clinical trial, FUJIFILM Corporation (Fujifilm) has exercised its o...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleShares in biotech Orthocell (ASX:OCC) are on the move again today after the company reported further...
Read Article04 Sep 2019 - Clinical-stage biotechnology company Cynata Therapeutics (ASX:CYP) is excited to have...
Read ArticlePharmaxis, one of last year’s biggest small cap reporting season winners, has tumbled 412 per cent i...
Read ArticleThe Credible Labs Inc (ASX: CRD) share price looks set to storm higher this morning after the San F...
Read ArticleJapanese company Sumitomo Dainippon Pharma has moved to acquire Australian cell therapy comp...
Read ArticleHealthcare being a large industry in Australia is a significant contributor to the country’s economy...
Read ArticleSponsored Content Sumitomo Dainippon Pharma, a $10 billion Japanese pharma company listed on the Tok...
Read ArticleThe S&P/ASX 200 index has charged higher on Friday thanks largely to strong gains in the bankin...
Read ArticleMelbourne's Cynata Therapeutics says it doesn't believe a $202 million takeover offer it disclosed o...
Read ArticleASX shares at the smaller end of the market are outperforming along with the Australian dollar as t...
Read ArticleStem cell manufacturer Cynata Therapeutics (ASX: CYP) has announced this morning it has received an...
Read ArticleThe Cynata Therapeutics Ltd (ASX: CYP) share price has been one of the best performers on the local...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleSpecial Report: Stem cells still have somewhat of a bad rep, as news headlines either repeat the emb...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
